Dublin, 14 August 2020 (GLOBE NEWSWIRE) – ResearchAndMarkets.com published a new article on the COVID-19 vaccine industry “Mass production of the Russian COVID-19 vaccine is expected to begin in September”
Russia now has the first country to sign a COVID-19 vaccine. In July, the World Health Organization reported that there were 26 candidate vaccines at the clinical evaluation stage, adding the signed vaccine in Russia. The viral vector vaccine, which began phase 3 clinical trials last week, was developed through the Gamaleya Institute in Moscow and the Russian Direct Investment Fund and is expected to provide coronavirus immunity for up to two years.
Russia has the fourth number of cases in the world with around 900,000 coronavirus infections. The Russian Ministry of Health intends to first offer the vaccine to fitness workers, teachers and other high-risk groups. Mass production of the vaccine is expected to begin in September with a mass vaccination crusade scheduled for October. The resolution to approve the vaccine has caused some controversy in the pharmaceutical industry, and industry organizations added the Clinical Trials Organization Association (OTCA), wondering why Russia has not yet published clinical knowledge demonstrating the effectiveness of the vaccine.
To see the full article and a list of similar market reports, “Mass production of the Russian COVID-19 vaccine is expected to begin in September”
Reseek and Markets also offers custom searches that offer a targeted, complete and personalized search.